Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Netupitant/palonosetron - Helsinn

Next Previous
Drug Profile

Netupitant/palonosetron - Helsinn

Alternative Names: AKYNZEO; Akynzeo; Fosnetupitant/palonosetron; NEPA - Helsinn; NEPA-IV; Palonosetron/Fosnetupitant; Palonosetron/netupitant

Latest Information Update: 14 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Helsinn
  • Developer CSL Vifor; Glenmark Pharmaceuticals Ltd; Helsinn; HK inno.N; Mundipharma International; Purdue Pharma; Taiho Pharmaceutical
  • Class Antiemetics; Isoquinolines; Pyridines; Quinuclidines; Small molecules
  • Mechanism of Action Neurokinin 1 antagonists; Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chemotherapy-induced nausea and vomiting

Most Recent Events

  • 01 Apr 2025 Helsinn plans a phase II trial for Chemotherapy-induced nausea and vomiting (Prevention, In neonates, In infants, In children, In adolescents) in Greece, Poland, Romania, Turkey (IV, Infusion), in April 2025 , (NCT06904235) (EudraCT2024-514321-39)
  • 08 Jan 2025 Netupitant/palonosetron licensed to ESTEVE in Germany
  • 12 Jun 2024 Netupitant/palonosetron licensed to Chugai Pharma Europe in Ireland and United Kingdom

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top